Tokyo Tape
Sign in
← CellSeed

Annual report

7776.TEDINET S100QIL1
Period2022-01-01 → 2022-12-31
Filed2023-03-31
StandardJapan GAAP
ConsolidatedNo
Data checks9 of 12 passed
Key figures · 110
MetricValuePeriodScopeSource row
Revenue¥126m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥162m2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥199m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥276m2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥1.0bn2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥743m2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥864m2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥754m2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥866m2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥887m2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥745m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥729m2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥786m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥787m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥141m2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥141m2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥759m2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥909m2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income (owners)−¥915m2021-01-01 → 2021-12-31StandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥784m2020-01-01 → 2020-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥782m2019-01-01 → 2019-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)¥130m2018-01-01 → 2018-12-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥760m2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥913m2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥768m2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥783m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income¥130m2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.5bnat 2022-12-31StandaloneAssets
Total assets¥1.4bnat 2021-12-31StandaloneAssets
Total assets¥1.4bnat 2021-12-31StandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.5bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.6bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total assets¥1.6bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥366mat 2022-12-31StandaloneLiabilities
Total liabilities¥364mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31StandaloneNet assets
Net assets / equity¥1.0bnat 2021-12-31StandaloneNet assets (5-year summary)
Net assets / equity¥1.6bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥1.5bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.3bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.4bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.4bnat 2018-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥1.4bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.1bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥847mat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥1.1bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥847mat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥931mat 2021-12-31StandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.5bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.1bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥718m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥817m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥701m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥578m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥307m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥62m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥110m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥13m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥133m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥882m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥397m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥721m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥25m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.182021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-53.082021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-55.312020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-54.192020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.62019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.682019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.352018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.382018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥11.272018-01-01 → 2018-12-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥11.32018-01-01 → 2018-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥47.26at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥56.44at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥57.43at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥93.85at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥95.7at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥102.24at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥103.88at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥121.19at 2018-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥122.78at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio74.8%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio72.0%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio83.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.5%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.3%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.5%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.3%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE9.8%2018-01-01 → 2018-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued24,422,619at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,759,419at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued16,008,319at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued12,981,819at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,459,419at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees30at 2022-12-31StandaloneNumber of employees
Employees44at 2021-12-31StandaloneNumber of employees
Employees40at 2020-12-31dStandaloneNumber of employees
Employees40at 2019-12-31dStandaloneNumber of employees
Employees39at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 21
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2022-01-01 → 2022-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥1.3bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥190m
Cell Sheet Regenerative Medicinereportable segmentemployeesat 2022-12-3119 pure
Cell Sheet Regenerative Medicinereportable segmentrevenue2022-01-01 → 2022-12-31¥10m
Cell Sheet Regenerative Medicinereportable segmentrevenue external2022-01-01 → 2022-12-31¥10m
Cell Sheet Regenerative Medicinereportable segmentsegment assetsat 2022-12-31¥82m
Cell Sheet Regenerative Medicinereportable segmentsegment profit2022-01-01 → 2022-12-31−¥463m
Laboratory Consumables And Equipmentreportable segmentcapex2022-01-01 → 2022-12-31¥563,000
Laboratory Consumables And Equipmentreportable segmentdepreciation2022-01-01 → 2022-12-31¥8m
Laboratory Consumables And Equipmentreportable segmentemployeesat 2022-12-317 pure
Laboratory Consumables And Equipmentreportable segmentrevenue2022-01-01 → 2022-12-31¥116m
Laboratory Consumables And Equipmentreportable segmentrevenue external2022-01-01 → 2022-12-31¥116m
Laboratory Consumables And Equipmentreportable segmentsegment assetsat 2022-12-31¥196m
Laboratory Consumables And Equipmentreportable segmentsegment profit2022-01-01 → 2022-12-31−¥90m
—segment totalcapex2022-01-01 → 2022-12-31¥563,000
—segment totaldepreciation2022-01-01 → 2022-12-31¥8m
—segment totalrevenue2022-01-01 → 2022-12-31¥126m
—segment totalrevenue external2022-01-01 → 2022-12-31¥126m
—segment totalsegment assetsat 2022-12-31¥277m
—segment totalsegment profit2022-01-01 → 2022-12-31−¥553m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 895
ItemContextValueUnit
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember1781000JPY
Write downs of inventoriesPrior1YearDuration_NonConsolidatedMember2272000JPY
Write downs of inventoriesCurrentYearDuration_NonConsolidatedMember-1109000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember116013000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember10414000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember126427000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember126427000JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember116013000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember10414000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember126427000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember126427000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember-90308000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember-462979000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember-553288000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-189927000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-743215000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember195771000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember81580000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember277351000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember1266569000JPY
AssetsCurrentYearInstant_NonConsolidatedMember1543920000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember36602000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember139270000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember175873000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember189709000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember365582000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember7891000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember7891000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember7891000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember563000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember563000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember3490000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember4054000JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000LaboratoryConsumablesAndEquipmentReportableSegmentsMember－JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember_UnallocatedAmountsAndEliminationMember3490000JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember3490000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 9 of 12 passed
balance sheet identitynon_consolidated 2021-12-31pass rounding
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-12-31mismatch
statement vs summary · net assetsnon_consolidated 2021-12-31mismatch
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31mismatch
statement vs summary · total assetsnon_consolidated 2022-12-31pass